Therapeutic Response

v::ALK status confers therapeutic sensitivity to Lorlatinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Lorbrena (lorlatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to lorlatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.
Lorbrena (lorlatinib) [product monograph]. HC. Health Canada approved lorlatinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).
Lorbrena (lorlatinib) [product monograph]. HC. Health Canada approved lorlatinib as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.